Cargando…

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )

After >2 years of the coronavirus disease 2019 (COVID-19) pandemic, immunoglobulins (IGs) contain highly potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, based on the large proportion of United States (US) plasma donors who have gone through COVID-19 or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farcet, Maria R, Karbiener, Michael, Knotzer, Simone, Schwaiger, Julia, Kreil, Thomas R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494343/ https://www.ncbi.nlm.nih.gov/pubmed/36052810 http://dx.doi.org/10.1093/infdis/jiac358

Ejemplares similares

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic
por: Schwaiger, Julia, et al.
Publicado: (2020)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
por: Farcet, Maria R., et al.
Publicado: (2022)

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
por: Karbiener, Michael, et al.
Publicado: (2021)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
por: Karbiener, Michael, et al.
Publicado: (2022)

Antibody‐enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin
por: Kapsch, Anna‐Maria, et al.
Publicado: (2020)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

Orthopox viruses and the safety margins of solvent‐detergent treated plasma‐derived medicinal products
por: Kindermann, Johanna, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Measuring the effectiveness of gaseous virus disinfectants
por: Knotzer, Simone, et al.
Publicado: (2015)

Longitudinal analysis of SARS‐CoV‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
por: Karbiener, Michael, et al.
Publicado: (2021)

High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster( )
por: Guirakhoo, Farshad, et al.
Publicado: (2022)

Decreased Risk of Coronavirus Disease 2019–Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
por: Ridgway, Jessica P, et al.
Publicado: (2022)

Croup during the Coronavirus Disease 2019 Omicron Variant Surge
por: Tunҫ, Emine M., et al.
Publicado: (2022)

Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies
por: Kang, Hyangju, et al.
Publicado: (2022)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection
por: Springer, David Niklas, et al.
Publicado: (2023)

Incidence and outcomes of hospital-associated coronavirus disease 2019 (COVID-19) before and after emergence of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron variant
por: Williams, Victoria R., et al.
Publicado: (2023)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler
por: Sexton, Mary Elizabeth, et al.
Publicado: (2022)

First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy
por: Micheli, Valeria, et al.
Publicado: (2022)

Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa( )
por: Samsunder, Natasha, et al.
Publicado: (2022)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Children and Utility of Rapid Antigen Testing as an Indicator of Culturable Virus
por: Lohse, Zoe M, et al.
Publicado: (2022)

Omicron evades immunity from vaccines
por: Onuora, Sarah
Publicado: (2022)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
por: Kagucia, E Wangeci, et al.
Publicado: (2021)

Transmission Potential of the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in South Korea, 25 November 2021–8 January 2022
por: Shim, Eunha, et al.
Publicado: (2022)

Investigating Blood Donors With Postdonation Respiratory Tract Symptoms During the Wild-Type, Delta, and Omicron Waves of the Coronavirus Disease 2019 Pandemic in England
por: Gates, Shannah, et al.
Publicado: (2023)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
por: Gaebler, Christian, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
por: Sitaras, Ioannis, et al.
Publicado: (2022)

A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron
por: Reyes-Alcaraz, Arfaxad, et al.
Publicado: (2023)

Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization
por: Zhang, Yuan, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_73rparjb1s5qddkc6q91ehvbbh